Mantle cell lymphoma: biological insights and treatment advances.

John P. Leonard, Michael E. Williams, Andre Goy, Steven Grant, Michael Pfreundschuh, Steve T. Rosen, John W. Sweetenham

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Mantle cell lymphoma (MCL) exhibits considerable molecular heterogeneity and complexity, and is regarded as one of the most challenging lymphomas to treat. With increased understanding of the pathobiology of MCL, it is proposed that MCL is the result of 3 major converging factors, namely, deregulated cell cycle pathways, defects in DNA damage responses, and dysregulation of cell survival pathways. In the present era of targeted therapies, these biologic insights have resulted in the identification of several novel rational targets for therapeutic intervention in MCL that are undergoing active clinical testing. To date, there is no standard of care in MCL. Several approaches including conventional anthracycline-based therapies and intensive high-dose strategies with and without stem cell transplantation have failed to produce durable remissions for most patients. Moreover, considering the heterogeneity of MCL, it is increasingly being recognized that risk-adapted therapy might be a relevant therapeutic approach in this disease. At the first and second Global Workshops on Mantle Cell Lymphoma, questions addressing advances in the pathobiology of MCL, optimization of existing therapies, assessment of current data with novel therapeutic strategies, and the identification of molecular or phenotypic risk factors for utilization in risk-adapted therapies were discussed and will be summarized herein.

Original languageEnglish (US)
Pages (from-to)267-277
Number of pages11
JournalClinical lymphoma & myeloma
Volume9
Issue number4
DOIs
StatePublished - Aug 2009
Externally publishedYes

Fingerprint

Mantle-Cell Lymphoma
Therapeutics
Biological Therapy
Anthracyclines
Stem Cell Transplantation
Standard of Care
DNA Damage
Lymphoma
Cell Survival
Cell Cycle
Education

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Leonard, J. P., Williams, M. E., Goy, A., Grant, S., Pfreundschuh, M., Rosen, S. T., & Sweetenham, J. W. (2009). Mantle cell lymphoma: biological insights and treatment advances. Clinical lymphoma & myeloma, 9(4), 267-277. https://doi.org/10.3816/CLM.2009.n.055

Mantle cell lymphoma : biological insights and treatment advances. / Leonard, John P.; Williams, Michael E.; Goy, Andre; Grant, Steven; Pfreundschuh, Michael; Rosen, Steve T.; Sweetenham, John W.

In: Clinical lymphoma & myeloma, Vol. 9, No. 4, 08.2009, p. 267-277.

Research output: Contribution to journalReview article

Leonard, JP, Williams, ME, Goy, A, Grant, S, Pfreundschuh, M, Rosen, ST & Sweetenham, JW 2009, 'Mantle cell lymphoma: biological insights and treatment advances.', Clinical lymphoma & myeloma, vol. 9, no. 4, pp. 267-277. https://doi.org/10.3816/CLM.2009.n.055
Leonard JP, Williams ME, Goy A, Grant S, Pfreundschuh M, Rosen ST et al. Mantle cell lymphoma: biological insights and treatment advances. Clinical lymphoma & myeloma. 2009 Aug;9(4):267-277. https://doi.org/10.3816/CLM.2009.n.055
Leonard, John P. ; Williams, Michael E. ; Goy, Andre ; Grant, Steven ; Pfreundschuh, Michael ; Rosen, Steve T. ; Sweetenham, John W. / Mantle cell lymphoma : biological insights and treatment advances. In: Clinical lymphoma & myeloma. 2009 ; Vol. 9, No. 4. pp. 267-277.
@article{287d38d89f6642e59d74427abaa47caf,
title = "Mantle cell lymphoma: biological insights and treatment advances.",
abstract = "Mantle cell lymphoma (MCL) exhibits considerable molecular heterogeneity and complexity, and is regarded as one of the most challenging lymphomas to treat. With increased understanding of the pathobiology of MCL, it is proposed that MCL is the result of 3 major converging factors, namely, deregulated cell cycle pathways, defects in DNA damage responses, and dysregulation of cell survival pathways. In the present era of targeted therapies, these biologic insights have resulted in the identification of several novel rational targets for therapeutic intervention in MCL that are undergoing active clinical testing. To date, there is no standard of care in MCL. Several approaches including conventional anthracycline-based therapies and intensive high-dose strategies with and without stem cell transplantation have failed to produce durable remissions for most patients. Moreover, considering the heterogeneity of MCL, it is increasingly being recognized that risk-adapted therapy might be a relevant therapeutic approach in this disease. At the first and second Global Workshops on Mantle Cell Lymphoma, questions addressing advances in the pathobiology of MCL, optimization of existing therapies, assessment of current data with novel therapeutic strategies, and the identification of molecular or phenotypic risk factors for utilization in risk-adapted therapies were discussed and will be summarized herein.",
author = "Leonard, {John P.} and Williams, {Michael E.} and Andre Goy and Steven Grant and Michael Pfreundschuh and Rosen, {Steve T.} and Sweetenham, {John W.}",
year = "2009",
month = "8",
doi = "10.3816/CLM.2009.n.055",
language = "English (US)",
volume = "9",
pages = "267--277",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "4",

}

TY - JOUR

T1 - Mantle cell lymphoma

T2 - biological insights and treatment advances.

AU - Leonard, John P.

AU - Williams, Michael E.

AU - Goy, Andre

AU - Grant, Steven

AU - Pfreundschuh, Michael

AU - Rosen, Steve T.

AU - Sweetenham, John W.

PY - 2009/8

Y1 - 2009/8

N2 - Mantle cell lymphoma (MCL) exhibits considerable molecular heterogeneity and complexity, and is regarded as one of the most challenging lymphomas to treat. With increased understanding of the pathobiology of MCL, it is proposed that MCL is the result of 3 major converging factors, namely, deregulated cell cycle pathways, defects in DNA damage responses, and dysregulation of cell survival pathways. In the present era of targeted therapies, these biologic insights have resulted in the identification of several novel rational targets for therapeutic intervention in MCL that are undergoing active clinical testing. To date, there is no standard of care in MCL. Several approaches including conventional anthracycline-based therapies and intensive high-dose strategies with and without stem cell transplantation have failed to produce durable remissions for most patients. Moreover, considering the heterogeneity of MCL, it is increasingly being recognized that risk-adapted therapy might be a relevant therapeutic approach in this disease. At the first and second Global Workshops on Mantle Cell Lymphoma, questions addressing advances in the pathobiology of MCL, optimization of existing therapies, assessment of current data with novel therapeutic strategies, and the identification of molecular or phenotypic risk factors for utilization in risk-adapted therapies were discussed and will be summarized herein.

AB - Mantle cell lymphoma (MCL) exhibits considerable molecular heterogeneity and complexity, and is regarded as one of the most challenging lymphomas to treat. With increased understanding of the pathobiology of MCL, it is proposed that MCL is the result of 3 major converging factors, namely, deregulated cell cycle pathways, defects in DNA damage responses, and dysregulation of cell survival pathways. In the present era of targeted therapies, these biologic insights have resulted in the identification of several novel rational targets for therapeutic intervention in MCL that are undergoing active clinical testing. To date, there is no standard of care in MCL. Several approaches including conventional anthracycline-based therapies and intensive high-dose strategies with and without stem cell transplantation have failed to produce durable remissions for most patients. Moreover, considering the heterogeneity of MCL, it is increasingly being recognized that risk-adapted therapy might be a relevant therapeutic approach in this disease. At the first and second Global Workshops on Mantle Cell Lymphoma, questions addressing advances in the pathobiology of MCL, optimization of existing therapies, assessment of current data with novel therapeutic strategies, and the identification of molecular or phenotypic risk factors for utilization in risk-adapted therapies were discussed and will be summarized herein.

UR - http://www.scopus.com/inward/record.url?scp=77449116884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449116884&partnerID=8YFLogxK

U2 - 10.3816/CLM.2009.n.055

DO - 10.3816/CLM.2009.n.055

M3 - Review article

C2 - 19717376

AN - SCOPUS:77449116884

VL - 9

SP - 267

EP - 277

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 4

ER -